Paper Review Records
All Paper Review Records
15 valid samples · Newest publication first
Review days = acceptance date − received date. PDF, DOI, and publisher-page sources are retained.
4
days
Informing the debate: hypomethylating agents/venetoclax or intensive chemotherapy to treat acute myeloid leukemias
AuthorsMichael Daunov; Yogen Saunthararajah
Affiliations1. Department of Hematology and Oncology, University Hospitals; 2. School of Medicine, Case Western Reserve University; 3. Taussig Cancer Institute, Cleveland Clinic
61
days
Philadelphia-negative B-cell acute lymphoblastic leukemia developing after treatment for multiple myeloma: a case report
AuthorsChen Glait Santar; Ben-Zion Katz
Affiliations1. The Cellular Immunophenotyping Unit, Hematology Institute, Tel Aviv Sourasky Medical Center
2
days
The role of radiotherapy in bridging to CAR T-cell therapy for high-grade B-cell lymphoma
AuthorsMichael MacManus; Mark Dowling
Affiliations1. Peter MacCallum Cancer Centre; 2. The Sir Peter McCallum Department of Oncology, University of Melbourne; 3. Royal Melbourne Hospital
143
days
The impact of radiotherapy on the therapeutic response of patients treated with CAR T-cell therapy for high-grade lymphoma: a systematic review
AuthorsMaïfa Belghoul; Andrea Kuhnl; Timothy Chevassut; Robin Sanderson; George Mikhaeel; Reuben Benjamin; Piers Patton; John Jones
Affiliations1. Department of Clinical Experimental Medicine, Brighton and Sussex Medical School; 2. University Hospitals Sussex NHS Trust; 3. King’s College Hospital
152
days
Linvoseltamab versus elranatamab for triple-class exposed relapsed or refractory multiple myeloma: an indirect treatment comparison
AuthorsJoshua Richter; Hans C. Lee; Sundar Jagannath; Jeffrey A. Zonder; James E. Hoffman; Zheng-Yi Zhou; Viviana Garcia-Horton; Mirko Fillbrunn; Hongjue Wang; Matthew Mattera; Timothy J. Inocencio; Yingxin Xu; James Harnett; Tito Roccia; Glenn S. Kroog; Karen Rodriguez Lorenc; Kate Knorr; Qiufei Ma; Naresh Bumma
Affiliations1. The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai; 2. Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center; 3. Karmanos Cancer Institute, Wayne State University School of Medicine; 4. University of Miami Health System; 5. Analysis Group, Inc.; 6. Regeneron Pharmaceuticals, Inc.; 7. The Ohio State University Comprehensive Cancer Center
89
days
Extending the prognostic value of red cell distribution width to nodal T follicular helper cell lymphoma
AuthorsMitsuaki Oura; Daisuke Ikeda; Atsushi Uehara; Rikako Tabata; Kentaro Narita; Masami Takeuchi; Kosei Matsue
Affiliations1. Division of Hematology/Oncology, Kameda Medical Center
67
days
Glofitamab for the treatment of relapsed/refractory hairy cell leukemia: a case report
AuthorsLinwei Tan; Xingtong Wang; Yangzhi Zhao; Jia Li; Junna Li; Ou Bai; Wei Guo
Affiliations1. Department of Hematology, The First Hospital of Jilin University
70
days
CPX‑351 vs. FLAG‑ida in patients with high-risk AML/MDS and MDS-related gene mutations: a subgroup analysis of the UK NCRI AML19 trial
AuthorsPriyanka Mehta; Roderick Murphy; Saemi Park; Stefan Faderl; Tomas Skacel; Abin Thomas; Sean Johnson; Alex Legg
Affiliations1. University Hospitals Bristol and Weston NHS Foundation Trust; 2. Jazz Pharmaceuticals plc; 3. Centre for Trials Research, Cardiff University
69
days
D-VRD vs. D-KRD induction in transplant-eligible multiple myeloma: a real-world comparison
AuthorsOren Pasvolsky; Curtis Marcoux; Denái R. Milton; Mark R. Tanner; Qaiser Bashir; Samer Srour; Neeraj Saini; Paul Lin; Jeremy Ramdial; Yago Nieto; Guilin Tang; Yosra Aljawai; Asad A. Haider; Bilal Islam; Hans C. Lee; Krina K. Patel; Mahmoud R. Gaballa; Partow Kebriaei; Sheeba K. Thomas; Robert Z. Orlowski; Richard E. Champlin; Elizabeth J. Shpall; Muzaffar H. Qazilbash
Affiliations1. Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center; 2. Division of Hematology, Dalhousie University; 3. Department of Biostatistics, The University of Texas MD Anderson Cancer Center; 4. Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center; 5. Department of Hematopathology, The University of Texas MD Anderson Cancer Center; 6. Department of Medicine, Dow University of Health Sciences; 7. Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center
72
days
Specialist palliative care access and end-of-life hospitalizations in acute leukemia: a nationwide register study
AuthorsAnnasofia Holopainen; Hanna-Riikka Lehto; Taru Kuittinen; Mikko Nuutinen; Kristiina Tyynelä-Korhonen; Annamarja Lamminmäki; Tiina Saarto; Timo Carpén
Affiliations1. Department of Hematology, Kuopio University Hospital, The Wellbeing Services County of North Savo; 2. Faculty of Health Sciences, Institute of Clinical Medicine, University of Eastern Finland; 3. Department of General Medicine, Division of Palliative Medicine, University of Turku; 4. Palliative Care Centre and Hospital at Home, The Wellbeing Services County of Western Uusimaa; 5. Nordic Healthcare Group; 6. Palliative Care Center, Päijät-Häme Wellbeing Services County; 7. Cancer Center, Kuopio University Hospital, The Wellbeing Services County of North Savo; 8. Palliative Care Center, Comprehensive Cancer Center, Helsinki University Hospital and University of Helsinki
Expert Matching · Case Demo
Turn Your Submission Goalsinto a Verifiable Journal Plan
Share your field, deadline, and author profile. CrushSCI uses real review records to suggest a title direction, shortlist journals, and estimate timelines.
Client
I work in environmental engineering and need an SCI paper published within three months. I have no grant funding or prominent co-author. Which journals could I target?
CrushSCI
Yes. We will first screen for feasibility against the 90-day deadline, then identify comparable papers without grant support or prominent co-authors. The final shortlist will prioritize research quality and journal scope.
- Suggested title
- Machine Learning and Life-Cycle Assessment for Predicting and Optimizing Carbon Emissions in Urban Wastewater Treatment
- Database shortlist
- Environmental Technology & Innovation
SampleLatest 5 valid paper samples from 2026
Average review96.4 days
Median77 days